5-HTP combined therapy
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- H LUNDBECK AS
- Publication Date
- 2009-07-01
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1 
Figure 2 
Figure 3
Abstract
Description
field of invention
[0001] The present invention relates to combination therapy and pharmaceutical compositions comprising 5-hydroxytryptophan and serotonin reuptake inhibitors with improved efficacy. Background of the invention
[0002] 5-Hydroxytryptophan (5-HTP) is the immediate precursor of serotonin (5-hydroxytryptamine; 5-HT). In vivo, 5-HTP is carboxylated to produce 5-HT. The level of 5-HT in the brain depends on the level of 5-HTP in the central nervous system (CNS). No transport molecules are required to transport 5-HTP across the blood-brain barrier. 5-HTP has been shown clinically to increase serotonin production in the brain and therefore 5-HTP administration has been proposed as a treatment for patients with mild or moderate depression (for review see Meyers, S., Altern Med Rev. 2000 Feb, 5 (1):64-71; and Birdsall, T.C., Altern Med Rev. 1998 Aug;3(4):271-80).
[0003] Serotonin reuptake inhibitors (SRIs) have become the therapy of choice in the treatment of ...